Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				NGR007 NCT00483509


2.		Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				NGR008 NCT00484211


3.		Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Pharmaceutical / Industry				NGR010 EUDRACT Number: 2006-005993-39, NCT00484276


4.		Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				NGR012 NCT00484432


5.		Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 80				Pharmaceutical / Industry				NGR006 NCT00483080


6.		Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas in First Line of Treatment for the Metastatic Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				NGR011 NCT00484341


7.		NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				NGR005 NCT00675012

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute